Shanghai Pharmaceuticals Holding Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
shpmy · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) measures how much investors pay for each dollar of the company's trailing earnings. SHPMY's current PE ratio of 10.29x is calculated by dividing its stock price of $7.60 by its TTM earnings per share of $1.57. +24.6% elevated vs 5Y avg 8.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%13.7x
MedianQ3 · 75%196.8x
Max
At 10.29x, SHPMY's current P/E is within its average historical range over the past 20 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Distribution · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Shanghai Pharmaceuticals Holding Co., LtdYou SHPMY | $5.6B | 10.29x | -58.9% | $1.57 |
 ConvaTec Group Plc CNVVF | $4.7B | 33.16x | +32.5% | $0.09 |
 ConvaTec Group Plc CNVVY | $5.2B | 37.72x | +50.7% | $0.35 |
 DiaSorin S.p.A. DSRLF | $4.5B | 24.15x | -3.5% | $2.68 |
 Getinge AB (publ) GNGBY | $5.5B | 26.30x | +5.1% | $8.29 |
 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited GZPHF | $6.2B | 8.37x | -66.6% | $1.79 |
 MatsukiyoCocokara & Co. MSMKF | $6.6B | 20.48x | -18.2% | $140.82 |
Industry Average 6 peers with valid PE | — | 25.03x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 7.47x | $7.70 | -24.5% | |
2024-12-31 FY2024 | 9.90x | $6.15 | -3.2% | |
2023-12-31 FY2023 | 10.23x | $5.10 | +47.3% | |
2022-12-31 FY2022 | 6.94x | $8.06 | +3.1% | |
2021-12-31 FY2021 | 6.73x | $8.96 | -2.2% | |
2020-12-31 FY2020 | 6.89x | $7.91 | -27.8% | |
2019-12-31 FY2019 | 9.54x | $7.18 | -26.3% | |
2018-12-31 FY2018 | 12.95x | $6.86 | +3.1% | |
2017-12-31 FY2017 | 12.56x | $6.55 | -19.3% | |
2016-12-31 FY2016 | 15.56x | $5.94 | +20.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) measures how much investors pay for each dollar of the company's trailing earnings. SHPMY's current PE ratio of 10.29x is calculated by dividing its stock price of $7.60 by its TTM earnings per share of $1.57.
Frequently asked questions
SHPMY pe ratio · 6 questionsSHPMY's current PE ratio is 10.29x as of 2026-06-09, based on a stock price of $7.60 and TTM EPS of $1.57. Data sourced from Financial Modeling Prep via SHPMY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Shanghai Pharmaceuticals Holding Co., Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09